Revvity
RVTY
About: Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
Employees: 11,000
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
30% more first-time investments, than exits
New positions opened: 65 | Existing positions closed: 50
3.1% more ownership
Funds ownership: 93.95% [Q1] → 97.05% (+3.1%) [Q2]
1% more funds holding
Funds holding: 521 [Q1] → 526 (+5) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 6 [Q1] → 6 (+0) [Q2]
7% less repeat investments, than reductions
Existing positions increased: 181 | Existing positions reduced: 195
7% less capital invested
Capital invested by funds: $11.9B [Q1] → $11.1B (-$869M) [Q2]
54% less call options, than puts
Call options by funds: $1.74M | Put options by funds: $3.74M
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
|
Raymond James
Andrew Cooper
|
$115
|
Outperform
Reiterated
|
29 Jul 2025 |
|
Stifel
Daniel Arias
|
$110
|
Hold
Maintained
|
29 Jul 2025 |
|
Evercore ISI Group
Vijay Kumar
|
$115
|
Outperform
Maintained
|
8 Jul 2025 |
|
B of A Securities
Derik De Bruin
|
$110
|
Buy
Maintained
|
26 Jun 2025 |
Financial journalist opinion
Based on 4 articles about RVTY published over the past 30 days
